Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a cornerstone for mediastinal staging in lung cancer; however, sampling of bulky or necrotic lymph nodes remains challenging, often leading to inadequate tissue for molecular analysis. This study aimed to compare the diagnostic accuracy and molecular adequacy of conventional EBUS, contrast-enhanced EBUS (CE-EBUS) and EBUS elastography in patients with hilar and mediastinal lymphadenopathies. We conducted a retrospective, single-center study from April 2021 until January 2025, including 74 consecutive patients with mediastinal or hilar lymphadenopathies suspicious for malignancy on computed tomography (CT) and/or positron emission tomography-CT using 18F-fluorodeoxyglucose (18F-FDG PET-CT) [maximum standardized uptake value (SUVmax) >2.5]. Patients with suspected autoimmune or lymphoproliferative disease were excluded. All lymph nodes were bulky (>30 mm) and/or showed radiologic necrosis. All patients were distributed into three groups based on the technique used for lymph node evaluation: Conventional EBUS (n=26), CE-EBUS (n=23), and elastography (n=25). CE-EBUS was performed following the intravenous administration of 4.8 mL sulphur hexafluoride. Final diagnosis was based on histopathology and clinical-radiological follow-up in negative cases. Molecular adequacy was defined as the availability of sufficient viable material for standard molecular analyses. Diagnostic accuracy and molecular adequacy were compared across techniques, including a subgroup analysis focusing on bulky or necrotic lymph nodes. Baseline demographic, clinical, radiologic, and metabolic characteristics were comparable across groups. Overall diagnostic accuracy did not differ significantly among techniques. In analyses adjusted for bulky and necrotic lymphadenopathy, CE-EBUS was associated with higher molecular adequacy compared with conventional EBUS, while no statistically significant differences were observed between conventional EBUS and elastography. CE-EBUS seems to improve diagnostic and molecular yield, particularly in bulky or necrotic lymph nodes, by identifying vital tissue. Elastography provides complementary stiffness information, enhancing overall lymph node characterization. These results could expand upon prior evidence supporting CE-EBUS utility in mediastinal staging.
Background/Objectives: Contrast-enhanced endobronchial ultrasound (CE-EBUS) is a minimally invasive technique that combines traditional endobronchial ultrasound (EBUS) with a contrast agent (sulfur hexafluoride), enhancing the visualization of blood flow in mediastinal and hilar lymph nodes. This study aimed to assess the use of CE-EBUS in patients with advanced neoplasms and hilar or mediastinal lymphadenopathy, particularly to improve diagnostic accuracy and expedite sample collection. Methods: A retrospective observational study was conducted from April 2021 to December 2023, involving 49 patients divided into two groups: EBUS (n = 26) and CE-EBUS (n = 23). Patients had advanced neoplasms with hilar and mediastinal lymphadenopathy, including bulky masses and nodal metastases with central necrosis. In the CE-EBUS group, 4.8 mL of sulfur hexafluoride was administered intravenously. Morphological, echogenic, and vascular characteristics, diagnostic accuracy, sample collection adequacy and molecular testing were compared between the groups. Results: The diagnostic accuracy in CE-EBUS was similar to EBUS (21 vs. 19 patients), with no significant difference (p = 0.100). However, for patients with bulky masses and necrosis, the molecular assessment rate was significantly higher in the CE-EBUS group (81.8%) compared to the EBUS group (33.3%) (p = 0.014). Conclusions: CE-EBUS-TBNA could improve the accuracy of molecular assessments in patients with bulky, necrotic lymphadenopathy and could help collect vital neoplastic tissue for molecular testing.
Background/Objectives: Thymomas are the most common tumors of the anterior mediastinum. While early-stage disease often has a favorable prognosis, therapeutic options in advanced stages remain limited. Moreover, the molecular profile of thymomas is still poorly characterized. In the present study, we explored the presence of targetable mutations and programmed death-ligand 1 (PD-L1) expression in a cohort of surgically resected thymomas. Furthermore, we investigated the correlation between PD-L1 expression, histological subtype, and risk of recurrence in patients who underwent curative-intent thymectomy. Methods: Mutational profiling was performed using a DNA-based NGS Cancer Panel of 16 genes. PD-L1 expression was evaluated via Tumor Proportion Score (TPS), and thymomas with TPS ≥ 50% were identified as high expressors. The associations with histological subtype and disease-free survival (DFS) were analyzed using logistic regression, Cox proportional hazards models, and Kaplan–Meier survival curves. Results: In our study, 2/37 (5.4%) of tested neoplasms (type AB and B2 thymoma) reported as a PIK3CA mutation; no other targetable mutations were observed. Moreover, high PD-L1 expression (≥50%) was reported in (15/37) 40.5% of patients and was significantly associated with aggressive histological subtypes (B2 and B3) (p < 0.001). Logistic regression analysis showed that high PD-L1 expression was a significant predictor of aggressive histology (McFadden’s R2 = 0.268, p < 0.001), with an odds ratio of 15.5 (95% CI: 2.9–83.4; p = 0.001). During follow-up, 5/37 (13.5%) of patients experienced disease recurrence; however, no significant difference in DFS was found between high and low PD-L1 expression groups. Conclusions: Our data confirm the presence of PIK3CA mutations in thymomas and encourage the exploration the potential role of molecular target therapy in this setting. Moreover, we underlined that high PD-L1 expression level is associated with more aggressive thymoma subtypes and may have a role as a prognostic biomarker. These findings support the need for further studies on the potential role of molecular and predictive pathology in thymic epithelial tumors.
Guillain-Barré syndrome (GBS) is a rare immune-mediated peripheral nerve disorder. Among non-infectious fac- tors, surgery has been identified as a potential trigger of the disease. This report presents the case of a 74-year- old man who developed GBS 15 days after a right lower lobectomy for lung adenocarcinoma. We present a case of a patient who was a former smoker who underwent uniportal video-assisted (U-VATS) right lower lobectomy for localized lung adenocarcinoma. Fifteen days after surgery, he exhibited bilateral low- er-limb weakness, widespread paresthesia, and postural instability. Comprehensive diagnostic workup, in- cluding clinical assessment, serological tests, cerebrospinal fluid (CSF) analysis, and nerve conduction studies (NCS), confirmed the diagnosis. Notably, CSF analysis revealed albumin-cytological dissociation, with albumin 453.2 mg/L, protein 757 mg/L, glucose 67 mg/dl, 3 white blood cells (WBC)/uL, and polymorphonucleates (PMN) 33%. NCS demonstrated motor and sensory abnormalities. Prompt administration of intravenous immunoglob- ulins (IVIG) 2 g/kg daily for 5 days resulted in complete recovery within 3 months. This case emphasizes the importance of prompt recognition and management of GBS as a postoperative com- plication. Neurological examination, neuroimaging, and electrophysiological studies are essential for accurate diagnosis. IVIG therapy remains a cornerstone in GBS management, with favorable outcomes observed in this case. Enhanced awareness among clinicians about the potential association between surgery and GBS is vital to prevent more serious complications and ensure optimal patient management. Further research is crucial to determine the precise pathogenesis and mechanisms of GBS following lung surgery.
Background: Pleurodesis is widely used to control malignant pleural effusion (MPE), but reliable pre-procedural predictors of success remain lacking. We assessed whether routinely available systemic inflammatory biomarkers predict short-term pleurodesis outcome and explored multidimensional inflammatory phenotypes. Methods: This retrospective single-center cohort included 144 patients who underwent pleurodesis for MPE between January 2021 and August 2025. Pre-procedural systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) were evaluated using receiver operating characteristic analysis. K-means clustering, principal component analysis, and uniform manifold approximation and projection were used for exploratory phenotyping. Results: Complete success occurred in 100 patients (69.4%), failure in 35 (24.3%), and partial response in 9 (6.3%). None of the biomarkers discriminated success from failure (AUC: SII, 0.471; NLR, 0.409; PLR, 0.490; CRP, 0.544). Three exploratory clusters showed crude success rates of 88.9%, 72.3%, and 61.5%, respectively, but substantial overlap and lack of external validation precluded clinical interpretation. Conclusions: Single pre-procedural systemic inflammatory biomarkers should not be used alone to select patients for pleurodesis. Prospective multicenter studies integrating systemic markers with pleural biology and mechanical factors are warranted.
We report the case of a 68-year-old male with a history of urothelial carcinoma and severe emphysema who developed a delayed pneumothorax following CT-guided radiofrequency ablation (RFA) of a pulmonary squamous cell carcinoma. Conservative management with chest drainage failed to resolve the air leak. Surgical revision via uniportal video-assisted thoracic surgery (UVATS) allowed identification of a necrotic subpleural lesion with active air leakage. Hemostatic and sealing agents (Hemopatch® and Tisseel®) were applied with long-term resolution of the complication. This case underscores the importance of surgical intervention in selected cases of persistent air leak post-RFA and the potential efficacy of biologic sealants when resection is not feasible.